{
 "id": "multiple-sclerosis",
 "name": "Multiple Sclerosis",
 "aliases": [
  "Multiple sclerosis (MS)"
 ],
 "acronyms": [
  "MS"
 ],
 "bodySystem": "neurological",
 "parent": null,
 "children": [],
 "edition": "2026-11",
 "merkleRoot": "006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6",
 "builtFrom": "program.status and program.eligibility facts, grouped by the condition registry",
 "counts": {
  "open": 0,
  "limited": 0,
  "waitlist": 1,
  "closed": 4
 },
 "funds": [
  {
   "fund": "Multiple Sclerosis",
   "organization": "Accessia Health",
   "status": "waitlist",
   "dateOnPage": null,
   "awardLevelUsd": null,
   "insuranceTypes": null,
   "pageSays": "The program page lists the program as At Capacity, Waitlist Open. Its tracks: privately insured track waitlist open (at capacity); publicly insured track waitlist open (at capacity). It shows no date.",
   "readOn": "2026-11-10",
   "source": "https://accessiahealth.org/program/multiple-sclerosis/"
  },
  {
   "fund": "Multiple Sclerosis",
   "organization": "Good Days",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": null,
   "insuranceTypes": null,
   "pageSays": "The page marks the fund as not currently open for new enrollments (the fund's list item on the page carries the class closed).",
   "readOn": "2026-11-08",
   "source": "https://mygooddays.org/patients/diseases-covered/"
  },
  {
   "fund": "Multiple Sclerosis - Medicare Access",
   "organization": "HealthWell Foundation",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": null,
   "insuranceTypes": null,
   "pageSays": "The page lists the fund as Closed.",
   "readOn": "2026-11-08",
   "source": "https://www.healthwellfoundation.org/disease-funds/"
  },
  {
   "fund": "Multiple sclerosis (MS)",
   "organization": "TotalAssist (Patient Advocate Foundation copay funds)",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": 8000,
   "insuranceTypes": [
    "Medicaid",
    "Medicare",
    "TRICARE"
   ],
   "pageSays": "The page lists the fund as Closed.",
   "readOn": "2026-11-08",
   "source": "https://totalassist.org/funds/"
  },
  {
   "fund": "Multiple sclerosis (MS) health equity",
   "organization": "TotalAssist (Patient Advocate Foundation copay funds)",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": 8000,
   "insuranceTypes": [
    "Medicaid",
    "Medicare",
    "TRICARE"
   ],
   "pageSays": "The page lists the fund as Closed.",
   "readOn": "2026-11-08",
   "source": "https://totalassist.org/funds/"
  }
 ],
 "drugsWhoseLabelNamesThisCondition": [
  {
   "ingredient": "Cladribine",
   "pages": [
    {
     "brand": "Mavenclad",
     "url": "https://omnirx.org/medicines/mavenclad"
    }
   ],
   "labelSentence": "Cladribine tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease in adults.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22407c52d5-6498-7da5-da35-acc9ca73ced3%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "MS Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/multiple-sclerosis-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Dimethyl Fumarate",
   "pages": [
    {
     "brand": "Tecfidera",
     "url": "https://omnirx.org/medicines/tecfidera"
    }
   ],
   "labelSentence": "Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22074d2820-6cb4-437a-8f6f-a21cb0a8ee02%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "MS Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/multiple-sclerosis-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Diroximel Fumarate",
   "pages": [
    {
     "brand": "Vumerity",
     "url": "https://omnirx.org/medicines/vumerity"
    }
   ],
   "labelSentence": "VUMERITY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%222d74414f-6b83-4ea2-9a95-3cecabbce774%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "MS Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/multiple-sclerosis-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Interferon Beta-1b",
   "pages": [
    {
     "brand": "Betaseron",
     "url": "https://omnirx.org/medicines/betaseron"
    }
   ],
   "labelSentence": "BETASERON is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%2266311f74-0472-4fa3-848a-06002ca0def5%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Bayer US Patient Assistance Foundation",
     "url": "https://www.patientassistance.bayer.us/en/about/bayer-products",
     "programPageIsExternal": true,
     "inCurrentList": true,
     "note": null,
     "listKind": "Bayer prescription medicines included in the program",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Ocrelizumab",
   "pages": [
    {
     "brand": "Ocrevus",
     "url": "https://omnirx.org/medicines/ocrevus"
    }
   ],
   "labelSentence": "Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults ...",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%229da42362-3bb5-4b83-b4bb-b59fd4e55f0d%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Ocrevus Access Solutions (via Genentech)",
     "url": "https://omnirx.org/assistance/ocrevus-patient-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "Genentech Patient Foundation",
     "url": "https://omnirx.org/assistance/genentech-access-solutions",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "Our Participating Medicines",
     "status": null,
     "statusRead": null
    },
    {
     "name": "MS Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/multiple-sclerosis-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Ofatumumab",
   "pages": [
    {
     "brand": "Kesimpta",
     "url": "https://omnirx.org/medicines/kesimpta"
    }
   ],
   "labelSentence": "KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%226a8a3f53-2062-48ff-9dbe-b939df133ca3%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "MS Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/multiple-sclerosis-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "Novartis Patient Assistance Foundation (NPAF)",
     "url": "https://pap.novartis.com/medications-list/",
     "programPageIsExternal": true,
     "inCurrentList": true,
     "note": null,
     "listKind": "NPAF medications list",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Teriflunomide",
   "pages": [
    {
     "brand": "Aubagio",
     "url": "https://omnirx.org/medicines/aubagio"
    }
   ],
   "labelSentence": "Teriflunomide tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%221824aae5-58af-43da-8231-435c8f118bc0%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "MS Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/multiple-sclerosis-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Corticotropin",
   "pages": [
    {
     "brand": "Acthar",
     "url": "https://omnirx.org/medicines/acthar"
    }
   ],
   "labelSentence": "Acute exacerbations of multiple sclerosis.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22110a17aa-6ed9-4458-8e67-1a742ce448e4%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Glatiramer Acetate",
   "pages": [
    {
     "brand": "Copaxone",
     "url": "https://omnirx.org/medicines/copaxone"
    }
   ],
   "labelSentence": "Glatiramer acetate injection is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%220aa4ff2a-ce8e-46cd-830f-a264cc582be2%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Interferon Beta-1a",
   "pages": [
    {
     "brand": "Avonex",
     "url": "https://omnirx.org/medicines/avonex"
    }
   ],
   "labelSentence": "REBIF is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22c6fcb5d2-8fcd-44fa-a838-b84ee5f44f0f%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  }
 ],
 "fundsForRelatedCosts": [],
 "note": "Each status is what the fund page said on readOn. It is not an eligibility determination. We hold only the organizations we read; no fund here does not mean no fund exists.",
 "licence": "CC BY 4.0 for the OmniRx compilation"
}